Affiliation:
1. Hasanuddin University , Makassar , Indonesia
2. Dr. Wahidin Sudirohusodo Hospital , Makassar , Indonesia
Abstract
Abstract
Objectives
Some hematological parameters were reported as markers to assess severity of COVID-19 patients. Comorbidities were risk factors for severe COVID-19. Differences in hematology profile based on severity and comorbidity, and correlation between hematology profile and Ct value were never studied at Makassar, Indonesia. The aim of this study were to know the differences of hematology profile based on severity and comorbidity, and the correlation between hematology profile and Ct value in COVID-19 patients.
Methods
This study was retrospective, cross-sectional of confirmed COVID-19 patients who had been hospitalized at Dr. Wahidin Sudirohusodo hospital, Makassar, since June to August 2020. Hematology profile, Ct value, comorbidity, and severity of COVID-19 patients were obtained from Hospital Information System Data.
Results
From 217 patients, subjects were 102 (47%) male dan 115 (53%) female, 127 mild-moderate patients (58.5%) and 90 severe patients (41.5%), 143 patients (65%) without comorbidity, 74 patients (35%) with comorbidity. White blood cells (WBC), red cell distribution width (RDW), neutrophil and monocyte count, and neutrophil lymphocyte ratio (NLR) were significantly higher in severe patients than mild-moderate patients (p<0.05), besides RBC, hemoglobin, hematocrit, lymphocyte and thrombocyte count were significantly lower in severe patients than mild-moderate patients (p<0.05). Hematology profile was not different significantly based on comorbidity and was not correlated significantly with Ct value, except eosinophil count (r=0.161; p=0.018).
Conclusions
We suggest that hematology profile could predict the severity of COVID-19 patients. Moreover, eosinophil count could be considered to predict the infectivity of patient with COVID-19.
Subject
Medical Laboratory Technology,Education,Medicine (miscellaneous)
Reference37 articles.
1. WHO Coronavirus Diseases (COVID-19) Dashboard. World Health Organization; 2020. Available from: https://covid19.who.int/ [Accessed 11 Oct 2020].
2. Distribution Map. Task force for the acceleration of handling COVID-19 in Indonesia; 2020. Available from: https://covid19.go.id/peta-sebaran/ [Accessed 11 Oct 2020].
3. WHO. Clinical management of COVID-19: interim guidance. World Health Organization; 2020. Available from: https://www.who.int/publications/i/item/clinical-management-of-COVID-19/ [Accessed 12 Jun 2020].
4. Aktas, G. Hematological predictors of novel coronavirus infection. Rev Assoc Med Bras 2021;67:1–2. https://doi.org/10.1590/1806-9282.67.suppl1.20200678.
5. Wu, Z, McGoogan, JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China summary of a report of 72314 cases from the Chinese center for disease control and prevention. JAMA 2020;323:1239–42. https://doi.org/10.1001/jama.2020.2648.